Changes in Body Composition with Ritonavir-Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96-Week Randomized, Controlled Study

被引：23

作者：

McComsey, Grace ^{[1
,2
]}

Rightmire, Anna ^{[3
]}

Wirtz, Victoria ^{[3
]}

Yang, Rong ^{[3
]}

Mathew, Marina ^{[3
]}

McGrath, Donnie ^{[3
]}

机构：

[1] Case Western Reserve Univ, Div Pediat Infect Dis & Rheumatol, Dept Pediat, Cleveland, OH 44106 USA

[2] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA

[3] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2009年 / 48卷 / 09期

关键词：

ANTIRETROVIRAL THERAPY; NAIVE SUBJECTS; LIPODYSTROPHY; EFAVIRENZ; MEN; FAT;

D O I：

10.1086/597776

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with stavudine and lamivudine. Both treatment groups had similar increases in trunk fat, but patients treated with ritonavir-boosted atazanavir had a significantly lower incidence of lipoatrophy.

引用

页码：1323 / 1326

页数：4